4-butyrolactone has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishiguro, H; Takeuchi, M; Tanaka, S; Toi, M; Tsuji, W; Ueno, T | 1 |
| Chen, K; Conti, PS; Li, G; Wang, J; Wang, X; Zong, S | 1 |
| Abrahamsson, A; Dabrosin, C; Lindahl, G; Saarinen, N | 1 |
| Bergman Jungeström, M; Dabrosin, C; Thompson, LU | 1 |
| Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K | 1 |
| Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Yamada, Y; Yonekura, K | 1 |
1 trial(s) available for 4-butyrolactone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Count; Chemokine CCL2; Drug Combinations; Endothelial Cells; Female; Fluorouracil; Humans; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Tegafur; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
5 other study(ies) available for 4-butyrolactone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage.
Topics: 4-Butyrolactone; Animals; Catalysis; CD13 Antigens; Cell Line, Tumor; Chromatography, High Pressure Liquid; Click Chemistry; Copper Radioisotopes; Dimerization; Female; Gene Expression Regulation; Humans; Liver; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligopeptides; Peptides; Positron-Emission Tomography; Tissue Distribution | 2014 |
Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Flax; Humans; Immunohistochemistry; Interleukin 1 Receptor Antagonist Protein; Lignans; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Stromal Cells; Tamoxifen | 2011 |
Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Estradiol; Female; Flax; Humans; Lignans; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Phytoestrogens; Umbilical Veins; Vascular Endothelial Growth Factor A | 2007 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Hydroxybutyrates; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Tegafur; Tumor Cells, Cultured; Uracil | 1999 |
[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Sodium Oxybate; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured; Uracil | 2000 |